941 results on '"Juliusson, Gunnar"'
Search Results
102. Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk
103. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor
104. Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden
105. Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia
106. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
107. Over 10 years relative median survival in MM patients ≤ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry
108. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
109. Mechanisms of anti-cancer action and pharmacology of clofarabine
110. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia
111. Cyclophosphamide Plus Dexamethasone Is An Efficient Initial Treatment Before High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: Results of A Randomized Comparison With Vincristine, Doxorubicin, and Dexamethasone
112. Supplemental Material2 - Supplemental material for Diagnostic imaging trends in the emergency department: an extensive single-center experience
113. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration
114. Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults
115. Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2′-deoxyadenosine
116. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group
117. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia
118. Immunological and Genetic Abnormalities in Chronic Lymphocytic Leukaemia: Impact of the Purine Analogues
119. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia
120. Abstract: treatment of patients with myelodysplastic syndromes with G-CSF and erythropoietin
121. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
122. Identification of a commonly amplified 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies
123. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
124. B-cell lymphoma in transplanted liver: Clinical, histological and radiological manifestations
125. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study
126. Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow
127. Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients
128. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RBI gene: evidence for a role of an adjacent locus
129. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine
130. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope
131. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
132. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
133. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities
134. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
135. Diagnostic imaging in adult non-cystic fibrosis bronchiectasis
136. Diagnostic imaging trends in the emergency department: an extensive single-center experience
137. Targetable genetic alterations of TCF4 ( E2-2 ) drive immunoglobulin expression in diffuse large B cell lymphoma
138. AML Xenografts Undergo Extensive Clonal Competition and Unmask Rare Clones in Patient Samples
139. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia
140. Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios
141. Hematopoietic Reconstitution with Autologous Stem Cells
142. Authors' reply: Hypocholesterolaemia in hairy cell leukaemia
143. Mechanisms Behind Hypocholesterolaemia in Hairy Cell Leukaemia.
144. Low-dose cladribine for symptomatic hairy cell leukaemia
145. 2-Chlorodeoxyadenosine Therapy in Chronic Lymphocytic Leukemia
146. Disease-relate hypocholesterolemia in patients with hairy cell leukemia: positive correlation with spleen size but not with tumor cell burden or low density lipoprotein receptor activity
147. 2-Chlorodeoxyadenosine For Patients With B-cell Chronic Lymphocytic Leukemia Resistant To Fludarabine
148. Complete remission of B-cell chronic lymphocytic leukaemia after oral cladribine
149. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor.
150. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.